United States Non-Insulin Therapies for Diabetes Market Report 2017

February 2017 | 115 pages | ID: U9F912123B4EN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Non-Insulin Therapies for Diabetes

Revenue, means the sales value of Non-Insulin Therapies for Diabetes

This report studies sales (consumption) of Non-Insulin Therapies for Diabetes in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering

• GSK
• Eli Lilly
• Sumitomo Dainippon Pharma
• Intarcia Therapeutics
• Servier
• Jiangsu Hansoh Pharmaceutical
• Novo Nordisk
• Emisphere
• Uni-Bio Science Group
• Takeda
• 3SBio
• Merck
• Dong-A Pharmaceutical
• Luye Pharma Group
• Eurofarma
• Geropharm
• Alkem Labs
• SatRx
• Pfizer
• Jiangsu Hengrui Medicine

Market Segment by States, covering

• California
• Texas
• New York
• Florida
• Illinois

Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into

• Alpha-Glucosidase Inhibitors
• Amylin Agonists
• Biguanides
• Dipeptidyl Peptidase-4 (DPP4) Inhibitors
• Glinides/Meglitinides
• GLP-1 Analogs/GLP-1 Agonists
• Sodium-Glucose Cotransporter2(SGLT2)Inhibitors
• Sulfonylureas
• Thiazolidinediones
• Others

Split by applications, this report focuses on sales, market share and growth rate of Non-Insulin Therapies for Diabetes in each application, can be divided into

• Hospital Pharmacy
• Retail Pharmacies
• Online Pharmacy
• Others

Contents

United States Non-Insulin Therapies for Diabetes Market Report 2017

1 NON-INSULIN THERAPIES FOR DIABETES OVERVIEW

1.1 Product Overview and Scope of Non-Insulin Therapies for Diabetes
1.2 Classification of Non-Insulin Therapies for Diabetes
  1.2.1 Alpha-Glucosidase Inhibitors
  1.2.2 Amylin Agonists
  1.2.3 Biguanides
  1.2.4 Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  1.2.5 Glinides/Meglitinides
  1.2.6 GLP-1 Analogs/GLP-1 Agonists
  1.2.7 Sodium-Glucose Cotransporter2(SGLT2)Inhibitors
  1.2.8 Sulfonylureas
  1.2.9 Thiazolidinediones
  1.2.10 Others
1.3 Application of Non-Insulin Therapies for Diabetes
  1.3.1 Hospital Pharmacy
  1.3.2 Retail Pharmacies
  1.3.3 Online Pharmacy
  1.3.4 Others
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Non-Insulin Therapies for Diabetes (2012-2022)
  1.4.1 United States Non-Insulin Therapies for Diabetes Sales and Growth Rate (2012-2022)
  1.4.2 United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2022)

2 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES COMPETITION BY MANUFACTURERS

2.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Non-Insulin Therapies for Diabetes Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Non-Insulin Therapies for Diabetes Average Price by Manufactures (2015 and 2016)
2.4 Non-Insulin Therapies for Diabetes Market Competitive Situation and Trends
  2.4.1 Non-Insulin Therapies for Diabetes Market Concentration Rate
  2.4.2 Non-Insulin Therapies for Diabetes Market Share of Top 3 and Top 5 Manufacturers
  2.4.3 Mergers & Acquisitions, Expansion

3 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) AND REVENUE (VALUE) BY STATES (2012-2017)

3.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by States (2012-2017)
3.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by States (2012-2017)
3.3 United States Non-Insulin Therapies for Diabetes Price by States (2012-2017)

4 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (2012-2017)

4.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Type (2012-2017)
4.2 United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2012-2017)
4.3 United States Non-Insulin Therapies for Diabetes Price by Type (2012-2017)
4.4 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2012-2017)

5 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Non-Insulin Therapies for Diabetes Sales and Market Share by Application (2012-2017)
5.2 United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES MANUFACTURERS PROFILES/ANALYSIS

6.1 GSK
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.1.2.1 Alpha-Glucosidase Inhibitors
    6.1.2.2 Amylin Agonists
  6.1.3 GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Eli Lilly
  6.2.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.2.2.1 Alpha-Glucosidase Inhibitors
    6.2.2.2 Amylin Agonists
  6.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Sumitomo Dainippon Pharma
  6.3.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.3.2.1 Alpha-Glucosidase Inhibitors
    6.3.2.2 Amylin Agonists
  6.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Intarcia Therapeutics
  6.4.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.4.2.1 Alpha-Glucosidase Inhibitors
    6.4.2.2 Amylin Agonists
  6.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Servier
  6.5.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.5.2.1 Alpha-Glucosidase Inhibitors
    6.5.2.2 Amylin Agonists
  6.5.3 Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Jiangsu Hansoh Pharmaceutical
  6.6.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.6.2.1 Alpha-Glucosidase Inhibitors
    6.6.2.2 Amylin Agonists
  6.6.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Novo Nordisk
  6.7.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.7.2.1 Alpha-Glucosidase Inhibitors
    6.7.2.2 Amylin Agonists
  6.7.3 Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Emisphere
  6.8.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.8.2.1 Alpha-Glucosidase Inhibitors
    6.8.2.2 Amylin Agonists
  6.8.3 Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Uni-Bio Science Group
  6.9.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.9.2.1 Alpha-Glucosidase Inhibitors
    6.9.2.2 Amylin Agonists
  6.9.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Takeda
  6.10.2 Non-Insulin Therapies for Diabetes Product Type, Application and Specification
    6.10.2.1 Alpha-Glucosidase Inhibitors
    6.10.2.2 Amylin Agonists
  6.10.3 Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 3SBio
6.12 Merck
6.13 Dong-A Pharmaceutical
6.14 Luye Pharma Group
6.15 Eurofarma
6.16 Geropharm
6.17 Alkem Labs
6.18 SatRx
6.19 Pfizer
6.20 Jiangsu Hengrui Medicine

7 NON-INSULIN THERAPIES FOR DIABETES MANUFACTURING COST ANALYSIS

7.1 Non-Insulin Therapies for Diabetes Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Non-Insulin Therapies for Diabetes Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2015
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES NON-INSULIN THERAPIES FOR DIABETES MARKET FORECAST (2017-2022)

11.1 United States Non-Insulin Therapies for Diabetes Sales, Revenue Forecast (2017-2022)
11.2 United States Non-Insulin Therapies for Diabetes Sales Forecast by Type (2017-2022)
11.3 United States Non-Insulin Therapies for Diabetes Sales Forecast by Application (2017-2022)
11.4 Non-Insulin Therapies for Diabetes Price Forecast (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

Methodology
Analyst Introduction
Data Source

The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Non-Insulin Therapies for Diabetes
Table Classification of Non-Insulin Therapies for Diabetes
Figure United States Sales Market Share of Non-Insulin Therapies for Diabetes by Type in 2015
Figure Alpha-Glucosidase Inhibitors Picture
Figure Amylin Agonists Picture
Figure Biguanides Picture
Figure Dipeptidyl Peptidase-4 (DPP4) Inhibitors Picture
Figure Glinides/Meglitinides Picture
Figure GLP-1 Analogs/GLP-1 Agonists Picture
Figure Sodium-Glucose Cotransporter2(SGLT2)Inhibitors Picture
Figure Sulfonylureas Picture
Figure Thiazolidinediones Picture
Figure Others Picture
Table Application of Non-Insulin Therapies for Diabetes
Figure United States Sales Market Share of Non-Insulin Therapies for Diabetes by Application in 2015
Figure Hospital Pharmacy Examples
Figure Retail Pharmacies Examples
Figure Online Pharmacy Examples
Figure Others Examples
Figure United States Non-Insulin Therapies for Diabetes Sales and Growth Rate (2012-2022)
Figure United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate (2012-2022)
Table United States Non-Insulin Therapies for Diabetes Sales of Key Manufacturers (2015 and 2016)
Table United States Non-Insulin Therapies for Diabetes Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Non-Insulin Therapies for Diabetes Sales Share by Manufacturers
Figure 2016 Non-Insulin Therapies for Diabetes Sales Share by Manufacturers
Table United States Non-Insulin Therapies for Diabetes Revenue by Manufacturers (2015 and 2016)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers
Table 2016 United States Non-Insulin Therapies for Diabetes Revenue Share by Manufacturers
Table United States Market Non-Insulin Therapies for Diabetes Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Non-Insulin Therapies for Diabetes Average Price of Key Manufacturers in 2015
Figure Non-Insulin Therapies for Diabetes Market Share of Top 3 Manufacturers
Figure Non-Insulin Therapies for Diabetes Market Share of Top 5 Manufacturers
Table United States Non-Insulin Therapies for Diabetes Sales by States (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Sales Share by States (2012-2017)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by States in 2015
Table United States Non-Insulin Therapies for Diabetes Revenue and Market Share by States (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by States (2012-2017)
Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by States (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Price by States (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Sales by Type (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Sales Share by Type (2012-2017)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Type in 2015
Table United States Non-Insulin Therapies for Diabetes Revenue and Market Share by Type (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Non-Insulin Therapies for Diabetes by Type (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Price by Type (2012-2017)
Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Type (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Sales by Application (2012-2017)
Table United States Non-Insulin Therapies for Diabetes Sales Market Share by Application (2012-2017)
Figure United States Non-Insulin Therapies for Diabetes Sales Market Share by Application in 2015
Table United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017)
Figure United States Non-Insulin Therapies for Diabetes Sales Growth Rate by Application (2012-2017)
Table GSK Basic Information List
Table GSK Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Figure GSK Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Eli Lilly Basic Information List
Table Eli Lilly Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Eli Lilly Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Sumitomo Dainippon Pharma Basic Information List
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Intarcia Therapeutics Basic Information List
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Intarcia Therapeutics Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Servier Basic Information List
Table Servier Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Servier Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Jiangsu Hansoh Pharmaceutical Basic Information List
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novo Nordisk Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Emisphere Basic Information List
Table Emisphere Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Emisphere Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Uni-Bio Science Group Basic Information List
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Uni-Bio Science Group Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table Takeda Basic Information List
Table Takeda Non-Insulin Therapies for Diabetes Sales, Revenue, Price and Gross Margin (2012-2017)
Table Takeda Non-Insulin Therapies for Diabetes Sales Market Share (2012-2017)
Table 3SBio Basic Information List
Table Merck Basic Information List
Table Dong-A Pharmaceutical Basic Information List
Table Luye Pharma Group Basic Information List
Table Eurofarma Basic Information List
Table Geropharm Basic Information List
Table Alkem Labs Basic Information List
Table SatRx Basic Information List
Table Pfizer Basic Information List
Table Jiangsu Hengrui Medicine Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Non-Insulin Therapies for Diabetes
Figure Manufacturing Process Analysis of Non-Insulin Therapies for Diabetes
Figure Non-Insulin Therapies for Diabetes Industrial Chain Analysis
Table Raw Materials Sources of Non-Insulin Therapies for Diabetes Major Manufacturers in 2015
Table Major Buyers of Non-Insulin Therapies for Diabetes
Table Distributors/Traders List
Figure United States Non-Insulin Therapies for Diabetes Production and Growth Rate Forecast (2017-2022)
Figure United States Non-Insulin Therapies for Diabetes Revenue and Growth Rate Forecast (2017-2022)
Table United States Non-Insulin Therapies for Diabetes Production Forecast by Type (2017-2022)
Table United States Non-Insulin Therapies for Diabetes Consumption Forecast by Application (2017-2022)
Table United States Non-Insulin Therapies for Diabetes Sales Forecast by States (2017-2022)
Table United States Non-Insulin Therapies for Diabetes Sales Share Forecast by States (2017-2022)